載入中
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
前收盤價
US$31.10
−US$0.02 · -0.06%
盤中時間採用ET。市場資料可能有所延遲。
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
日內區間
目前US$31.10
52週區間
目前US$31.10
盤中時間採用ET。市場資料可能有所延遲。
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
日內區間
目前US$31.10
52週區間
目前US$31.10
營業利益
淨利
| 項目（EUR） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1.24億 EUR | 9856.35萬 EUR | 6557.5萬 EUR | 5737.56萬 EUR | 3578.92萬 EUR |
| 銷售、一般及管理費用 | 4534.46萬 EUR | 4712.46萬 EUR | 3133.86萬 EUR | 2933.9萬 EUR | 1834.95萬 EUR |
| 營業費用 | 1.7億 EUR | 1.46億 EUR | 9691.36萬 EUR | 8671.46萬 EUR | 5413.86萬 EUR |
| 利息收入 | — | 546.9萬 EUR | — | 16.11 EUR | 267.51 EUR |
| 利息支出 | — | — | — | 1.61萬 EUR | 27.82萬 EUR |
| 折舊和攤銷 | 41.84萬 EUR | 26.96萬 EUR | 25.76萬 EUR | 15.29萬 EUR | 7.74萬 EUR |
| 營業利益 | −1.7億 EUR | −1.46億 EUR | −9691.36萬 EUR | −8671.46萬 EUR | −5413.86萬 EUR |
| 淨利 | −1.76億 EUR | −1.34億 EUR | −1.01億 EUR | −7633.26萬 EUR | −4273.08萬 EUR |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$60.73
上漲空間 95.27%報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB797.37萬0.08%108.2億 USD0.44%US$206.49+3.00%
iShares Core MSCI EAFE ETFIEFA405.09萬0.00%1894.71億 USD0.07%US$96.52+0.68%
iShares MSCI EAFE Small-Cap ETFSCZ261.19萬0.02%128.85億 USD0.40%US$83.93+0.82%
iShares MSCI Netherlands ETFEWN164.37萬0.23%7.02億 USD0.50%US$66.64+0.70%
Fidelity Nasdaq Composite Index ETFONEQ81.24萬0.01%109.4億 USD0.21%US$107.81+0.63%
iShares International Country Rotation Active ETFCORO40.41萬0.00%131.46億 USD1.06%US$36.17+0.61%
Virtus Biotech Clinical Trials ETFBBC32.15萬0.78%4099.65萬 USD0.65%US$44.1456+2.08%
Fidelity Disruptive Medicine ETFFMED22.1萬0.45%5231萬 USD0.50%US$31.4003+2.73%iShares Biotechnology ETFIBBiShares Core MSCI EAFE ETFIEFAiShares MSCI EAFE Small-Cap ETFSCZiShares MSCI Netherlands ETFEWNFidelity Nasdaq Composite Index ETFONEQiShares International Country Rotation Active ETFCOROVirtus Biotech Clinical Trials ETFBBCFidelity Disruptive Medicine ETFFMEDAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
